NuCana PLC
NCNA0.044USD
+0.005+12.28%
Market hours （ET）Quotes delayed by 15 min
266.78KMarket Cap
LossP/E TTM
More Details of NuCana PLC Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
Ticker SymbolNCNA
Company nameNuCana PLC
IPO dateSep 28, 2017
CEO- -
Number of employees20
Security typeDepository Receipt
Fiscal year-endSep 28
AddressLochside House
CityEDINBURGH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeEH12 9DT
Phone4401313571111
Websitehttps://www.nucana.com/
Ticker SymbolNCNA
IPO dateSep 28, 2017
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Adam George
Mr. Adam George
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Shareholders
Shareholders
Proportion
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Shareholder Types
Shareholders
Proportion
Venture Capital
0.09%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.01%
Investment Advisor
0.01%
Other
99.85%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
51
579.39K
0.15%
+67.06K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sofinnova Investments, Inc
199.52K
0.05%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
0.03%
--
--
Apr 18, 2025
Baader Bank AG
10.03K
0%
+10.03K
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
44.77K
0.01%
-300.00
-0.67%
Mar 31, 2025
Acadian Asset Management LLC
38.32K
0.01%
-4.09K
-9.65%
Mar 31, 2025
XTX Markets LLC
20.16K
0.01%
+20.16K
--
Mar 31, 2025
Glass Jacobson Wealth Advisors
15.00K
0%
--
--
Dec 31, 2024
Griffith (Hugh S)
10.60K
0%
--
--
Dec 31, 2024
LUNIS Vermögensmanagement AG
8.90K
0%
-1.00
-0.01%
Sep 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Date
Type
Ratio
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
